Heyholder

This is an amended filing · View original →

‹ Activism Filings

SLSBio(Specialty Lab Solution Bio) Co., Ltd Q3 revenue KRW 1.7 billion, loss of KRW 0.8 billion from main business

SLSBio(Specialty Lab Solution Bio) Co., Ltd· Periodic ReportAmended

AI summary · Not investment advice

In Q3, the company sold KRW 1.7 billion worth and lost KRW 0.8 billion from its main business; sales rose 459.7% from a year earlier and 27.8% from the prior quarter.

Operating profit · 3 months

KRW -810.5 million

Key facts

Revenue (3 months)
KRW 1.7 billion
Net income (3 months)
KRW -819.1 million
Revenue (prior-year 3 months)
KRW 295.7 million
Revenue (year to date)
KRW 3.9 billion
Operating profit (prior-year 3 months)
KRW -1.8 billionOperating loss
Operating profit (year to date)
KRW -2.7 billionOperating loss
Net income (prior-year 3 months)
KRW -1.9 billionNet loss
Net income (year to date)
KRW -2.7 billionNet loss

Commentary

AI commentary · Not investment advice

What happened

SLS Bio filed its quarterly report for the third quarter of 2026 on a standalone basis. Sales for the latest 3 months were KRW 1.66 billion. Sales for the same 3 months a year earlier were KRW 295.7 million. That is up 459.7% from a year earlier and up 27.8% from the previous quarter. Cumulative sales this year are KRW 3.91 billion.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 810.5 million. A year earlier, the same 3 months showed a loss of KRW 1.80 billion. The cumulative operating loss this year is KRW 2.66 billion.

What changes for shareholders

Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 819.1 million. A year earlier, the same 3 months showed a net loss of KRW 1.87 billion. The cumulative net loss this year is KRW 2.73 billion.

Comments

No comments yet

Comments from shareholders will appear here.